AI in Pharma (2025)

Jeremy Wildfire, Sri Pavan Vemuri & Satish Murthy

Best Practices for AI-Assisted R Coding and Data Workflows; What would an “AI-friendly” submission look like?; Reimagine open-label trial deliverables with interactive display/AI

2025
AI
Authors

Jeremy Wildfire

Sri Pavan Vemuri

Satish Murthy

Published

September 15, 2025

AI in Pharma

Chairs: Jeremy Wildfire, Sri Pavan Vemuri and Satish Murthy

See also: 2023 Discussion, 2024 Discussion

Current Use Cases

  • Development Support: Chatbots, ADM, Adam TLF coding standards, general coding support and automation
  • Specification Generation: Potential for generating specifications from SAPs and study documents to complete the code generation loop
  • Clinical Operations:
    • Improving operational efficiency
    • Signal detection for safety monitoring

Implementation Strategy

  • Break problems into manageable pipelines
  • Start with proof-of-concepts (POCs)
  • Leverage domain knowledge as a key asset

Technical Challenges

  • Data Privacy: Major concern with handling sensitive clinical data securely
  • Quality Control: Issues with traceability, repeatability, and quality control
  • AI Limitations: Hallucination problems with AI outputs
  • Implementation Issues: Tendency to over-engineer solutions rather than creating manageable ones

Organizational Barriers

  • Management Resistance: Leadership not being on board due to established habits
  • ROI Challenges: Difficulty demonstrating return on investment
  • Validation Requirements: Need for repeatability and validation processes
  • Training Needs: Comprehensive user training required for process changes
  • Job Security Concerns: Worries about AI-related job displacement

Regulatory and Compliance Issues

  • Audit Trail: Maintaining proper audit trails
  • Documentation: Ensuring complete documentation and transparency of AI pathways
  • Quality Standards: Meeting industry quality standards
  • Data Governance: Implementing proper guardrails and controls on sensitive data